Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,896,381
  • Shares Outstanding, K 91,480
  • Annual Sales, $ 59,320 K
  • Annual Income, $ -255,130 K
  • 60-Month Beta 2.88
  • Price/Sales 32.49
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYOV with:

Options Overview

Details
  • Implied Volatility 79.56%
  • Historical Volatility 39.89%
  • IV Percentile 9%
  • IV Rank 13.81%
  • IV High 186.76% on 09/24/20
  • IV Low 62.38% on 08/19/20
  • Put/Call Vol Ratio 0.15
  • Today's Volume 726
  • Volume Avg (30-Day) 1,144
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 34,006
  • Open Int (30-Day) 32,337

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.37
  • Number of Estimates 4
  • High Estimate -0.01
  • Low Estimate -0.83
  • Prior Year -0.37
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.46 +2.88%
on 06/18/21
24.90 -15.46%
on 05/26/21
-1.55 (-6.86%)
since 05/18/21
3-Month
16.69 +26.12%
on 04/13/21
25.51 -17.48%
on 03/22/21
-3.09 (-12.80%)
since 03/18/21
52-Week
13.42 +56.86%
on 10/02/20
30.90 -31.88%
on 12/28/20
+4.35 (+26.05%)
since 06/18/20

Most Recent Stories

More News
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More

The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.

BIIB : 388.44 (+1.28%)
ALKS : 24.42 (-1.09%)
PFE : 38.81 (-1.70%)
MRNA : 199.19 (-1.62%)
MYOV : 21.05 (+1.54%)
CVAC : 61.94 (+7.11%)
Myovant Sciences to Present at Upcoming Investor Conferences

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:...

MYOV : 21.05 (+1.54%)
Here's Why Pfizer (PFE) Has Been Rallying This Year So Far

Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.

PFE : 38.81 (-1.70%)
MYOV : 21.05 (+1.54%)
BNTX : 212.42 (-0.83%)
VTRS : 14.26 (-2.79%)
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE(R), the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

-- Myovant to host conference call and webcast on Friday, May 28, 2021 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time

MYOV : 21.05 (+1.54%)
PFE : 38.81 (-1.70%)
Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical Development and Corporate Achievements Across its Portfolio of Companies

LONDON and NEW YORK, /PRNewswire/ --  Biopharma, Inc. today announced that its portfolio of four wholly owned subsidiary companies (, ,  and )  and (NYSE: MYOV), a publicly listed company that...

MYOV : 21.05 (+1.54%)
Myovant Sciences Receives Positive CHMP Opinion for RYEQO(R) (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

-- Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe

MYOV : 21.05 (+1.54%)
Progressive, Iovance fall; Target, Take-Two rise

NEW YORK (AP) — Target Corp., up $12.58 to $219.01.

TGT : 230.53 (-0.30%)
TSLA : 623.31 (+1.09%)
EXP : 136.05 (-1.33%)
RETA : 138.00 (-1.31%)
TTWO : 171.28 (+0.46%)
MYOV : 21.05 (+1.54%)
PGR : 92.31 (+0.51%)
Myovant Sciences (MYOV) Reports Q4 Loss, Tops Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 10.10% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

MYOV : 21.05 (+1.54%)
Myovant Sciences: Fiscal Q4 Earnings Snapshot

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $81.4 million in its fiscal fourth quarter.

MYOV : 21.05 (+1.54%)
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the fourth fiscal quarter and fiscal year...

MYOV : 21.05 (+1.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

3rd Resistance Point 22.25
2nd Resistance Point 21.78
1st Resistance Point 21.41
Last Price 21.05
1st Support Level 20.57
2nd Support Level 20.10
3rd Support Level 19.73

See More

52-Week High 30.90
Fibonacci 61.8% 24.22
Fibonacci 50% 22.16
Last Price 21.05
Fibonacci 38.2% 20.10
52-Week Low 13.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar